Prof. Dr. med. Lars Bullinger

University Education

• 1992-1997 Heidelberg Medical School, Heidelberg, Germany
• 1998 Baylor College of Medicine, Houston, and Duke University, Durham, USA
• 1999 MD, Heidelberg Medical School 2000 Dr. med. (University of Heidelberg)
• 2008 Habilitation (University of Ulm) 2011 Assistant Prof. (apl. Professor), Internal Medicine (University of Ulm)
• 2016 Associate Prof. (Univ. Prof., W3), Personalized Medicine (University of Ulm)
• 2017 Full Professor (Univ. Prof., W3), Hematology / Oncology (Charité Berlin)

Professional Experience (selection)

• 2010 Sabbatical in the Department of Pediatric Oncology (Prof. S. A. Armstrong), Dana Farber Cancer Institute, Harvard Medical School, MA, USA
• 2011-2017 Attending Physician, Department of Internal Medicine III (Prof. H. Döhner), University Hospital of Ulm, Ulm, Germany
• 2013-2017 Head of the Oncology Section of the Department of Internal Medicine III (Prof. H. Döhner), University Hospital of Ulm, Ulm, Germany
• 2016-2017 Executive deputy director, Center of Internal Medicine; University Hospital of Ulm, Germany
• 2016-2017 Professor for Personalized Medicine (W3), Medical Faculty University of Ulm, Germany
• Since 2017 Director of the Department of Hematology, Oncology and Tumorimmunology (CVK), Charité University Medicine, Berlin, Germany

Research Fields

Our lab is committed to unravelling the genomic, epigenomic and transcriptomic changes leading up to and driving acute myeloid leukemia (AML) and other hematological malignancies. To this end, we employ massively parallelized next-generation sequencing (NGS) technologies, from Illumina and Oxford nanopore, to compare patient-derived primary tumor and matched control samples. Data analysis is developed and performed in-house by our own small team of bioinformaticians; findings of interest are followed up by functional validation in the lab. With close ties to the clinic, we are thus able to connect bench and bedside with our research in a dynamic exchange between dry in-silico and hands-on wet lab work. We are also well connected internationally and, for example, heavily involved in large cooperative projects such as SyTASC, SYNtherapy, and HARMONY.

haema-onko-cvk.charite.de/forschung/arbeitsgruppen/ag_bullinger/

Most important Awards, Grants or Scientific Achievements

• 1998 DAAD scholarship
• 2002-2003 DFG research scholarship
• 2005 Franziska Kolb award for leukemia research
• 2011-2014 Heisenberg scholarship (DFG)
• 2015 Heisenberg Professor (DFG)

Selected References

• Jayavelu, A. K., Schnöder, T. M., Perner, F., Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R., Brandt, S., Palandri, F., Schröder, N., Isermann, B., Edlich, F., Sinha, A. U., Ungelenk, M., Hübner, C. A., Zeiser, R., Rahmig, S., … Heidel, F. H. (2020). Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 588(7836), 157–163.
• Weller, J., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Bähr, O., Uhl, M., Seidel, C., Tabatabai, G., Brehmer, S., Bullinger, L., Galldiks, N., Schaub, C., Kebir, S., Stummer, W., Simon, M., … Schäfer, N. (2019). Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology, 20(10), 1444–1453.
• Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R. D., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Bähr, O., Uhl, M., Seidel, C., Tabatabai, G., Kowalski, T., Ringel, F., Schmidt-Graf, F., Suchorska, B., … Neurooncology Working Group of the German Cancer Society (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet (London, England), 393(10172), 678–688.
• Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., Bahr, C., Zeisberger, P., Przybylla, A., Sohn, M., Tönjes, M., Erez, A., Adler, L., Jensen, P., Scholl, C., Fröhling, S., … Trumpp, A. (2018). Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature, 560(7718), E28.
• Gozdecka, M., Meduri, E., Mazan, M., Tzelepis, K., Dudek, M., Knights, A. J., Pardo, M., Yu, L., Choudhary, J. S., Metzakopian, E., Iyer, V., Yun, H., Park, N., Varela, I., Bautista, R., Collord, G., Dovey, O., Garyfallos, D. A., De Braekeleer, E., Kondo, S., … Huntly, B. (2018). UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nature genetics, 50(6), 883–894.
• Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., Bahr, C., Zeisberger, P., Przybylla, A., Sohn, M., Tönjes, M., Erez, A., Adler, L., Jensen, P., Scholl, C., Fröhling, S., … Trumpp, A. (2017). BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature, 551(7680), 384–388.
• Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., Heuser, M., Thol, F., Bolli, N., Ganly, P., Ganser, A., McDermott, U., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J. (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature genetics, 49(3), 332–340.
• Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O'Meara, S., Raine, K., Jones, D. R., Teague, J. W., … Campbell, P. J. (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England journal of medicine, 374(23), 2209–2221.
• Ng, S. W., Mitchell, A., Kennedy, J. A., Chen, W. C., McLeod, J., Ibrahimova, N., Arruda, A., Popescu, A., Gupta, V., Schimmer, A. D., Schuh, A. C., Yee, K. W., Bullinger, L., Herold, T., Görlich, D., Büchner, T., Hiddemann, W., Berdel, W. E., Wörmann, B., Cheok, M., … Wang, J. C. (2016). A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 540(7633), 433–437.
• Faber, Z. J., Chen, X., Gedman, A. L., Boggs, K., Cheng, J., Ma, J., Radtke, I., Chao, J. R., Walsh, M. P., Song, G., Andersson, A. K., Dang, J., Dong, L., Liu, Y., Huether, R., Cai, Z., Mulder, H., Wu, G., Edmonson, M., Rusch, M., … Downing, J. R. (2016). The genomic landscape of core-binding factor acute myeloid leukemias. Nature genetics, 48(12), 1551–1556.
• Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., Svinkina, T., Schneider, R. K., McConkey, M., Järås, M., Griffiths, E., Wetzler, M., Bullinger, L., Cathers, B. E., Carr, S. A., Chopra, R., … Ebert, B. L. (2015). Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature, 523(7559), 183–188.
• Sander, S., Chu, V. T., Yasuda, T., Franklin, A., Graf, R., Calado, D. P., Li, S., Imami, K., Selbach, M., Di Virgilio, M., Bullinger, L., & Rajewsky, K. (2015). PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones. Immunity, 43(6), 1075–1086.
• Bruedigam, C., Bagger, F. O., Heidel, F. H., Paine Kuhn, C., Guignes, S., Song, A., Austin, R., Vu, T., Lee, E., Riyat, S., Moore, A. S., Lock, R. B., Bullinger, L., Hill, G. R., Armstrong, S. A., Williams, D. A., & Lane, S. W. (2014). Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell stem cell, 15(6), 775–790.
• Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., Döhner, H., & German-Austrian Acute Myeloid Leukemia Study Group (2008). Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England journal of medicine, 358(18), 1909–1918.
• Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. The New England journal of medicine, 343(26), 1910–1916.